[1] Lambie M, Bonomini M, Davies SJ, et al.Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis[J]. Trends Endocrinol Metab,2021,32(9):721-730. [2] Azevedo CAB, da Cunha RS, Junho CVC, et al. Extracellular Vesicles and Their Relationship with the Heart-Kidney Axis, Uremia and Peritoneal Dialysis[J]. Toxins (Basel),2021,13(11):778-782. [3] 王娟,朱孝明. 缬沙坦联合血液透析治疗尿毒症合并顽固性高血压的临床效果[J]. 临床医学研究与实践,2020,5(11):31-32. [4] Lambie M, Bonomini M, Davies SJ, et al.Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis[J]. Trends Endocrinol Metab,2021,32(9):721-730. [5] 沈文安,杨海玲,罗小芳. 血液透析-灌流对尿毒症顽固性高血压患者血压的改善及满意度观察[J]. 心血管病防治知识,2021,11(29):12-14. [6] Tang X, Wang J, Li H, et al.Hemoperfusion combined with hemodialysis filtration can effectively improve uremia complicated with bone and mineral disorders[J]. Panminerva Med,2021,63(3):394-395. [7] 葛均波,徐永健,王辰.内科学[M].第8版.北京:人民卫生出版社, 2014. [8] 谢镇林. 血液灌流联合血液透析治疗尿毒症患者伴顽固性高血压疗效的观察[J]. 现代诊断与治疗,2019,30(12):1974-1976. [9] 宋培. 血液灌流联合血液透析对尿毒症患者肾功能及T淋巴细胞水平的影响[J]. 河北医学,2019,25(8):1253-1257. [10] 徐保振,武美娟,胡秀红,等. 雷公藤多苷对慢性肾脏病大鼠血管内皮损伤的保护作用及其机制[J]. 吉林大学学报(医学版),2021,47(2):377-383. [11] 蒲辉,周红丽. 血液透析联合血液灌流治疗尿毒症顽固性高血压疗效分析[J]. 中国中西医结合肾病杂志,2019,20(2):161-162. |